A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004)
Conditions: Renal Cell Carcinoma Interventions: Biological: V940; Biological: Pembrolizumab; Biological: Placebo Sponsors: Merck Sharp& Dohme LLC; ModernaTX, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Merck | Renal Cell Carcinoma | Research | Study